Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Pfizer’s pricing deal with the Trump administration, which won the company a three-year exemption from sector-specific ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Pfizer › A strong quarter and earnings beat can sometimes give a stock a big boost. But when that doesn't happen, it usually means there are other factors that are weighing on a business and give ...

Pfizer offers a 7% dividend yield, lower COVID sales, oncology and cardiometabolic focus, and growth from Metsera and ...

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on ...

Pfizer (NYSE:PFE) stock rose 0.6% after the U.S. pharma giant clinched a $10 billion deal for obesity drug developer Metsera, ...

Investing.com - U.S. stock futures rose sharply Monday after the Senate voted in favor of a bill aimed at ending the ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...

The Metsera deal is about winning the obesity drugs' market that’s expected to reach US$100 billion by 2030. Read more at ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...